AR
ARDS.US Aridis Pharmaceuticals Inc
- Market cap
- USD 4.46K
- P/E
- -
- P/B
- 5.40x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is ARDS.US undervalued?
Graham numberThe Graham number of Aridis Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aridis Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Aridis Pharmaceuticals Inc yet.
Aridis Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to …
Full company profileAridis Pharmaceuticals Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aridis Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 2.86M | 2.27M | 860K | 2.76M | 1.02M | 1.00M | 1.54M | 19.3M | 26.8M |
| Gross Profit | 714K | 342K | 860K | 2.76M | 1.02M | 1.00M | 1.54M | - | - |
| Operating Income | -7.91M | -7.88M | -19.7M | -24.1M | -29.1M | -22.4M | -43.7M | -30.0M | 8.72M |
| EBITDA | - | -7.86M | -19.7M | -23.8M | -28.7M | 31.5M | -43.0M | -29.5M | 8.99M |
| Net Income | -8.20M | -8.42M | -24.7M | -22.1M | -29.0M | -22.3M | -42.3M | -30.7M | 6.99M |
| EPS | - | -1.07 | -3.12 | -7.02 | -3.43 | -2.44 | -3.44 | -1.64 | 0.19 |
| Balance Sheet | |||||||||
| Total Assets | 3.88M | 22.5M | 26.5M | 31.6M | 28.0M | 15.1M | 26.8M | 14.7M | 6.53M |
| Total Liabilities | 5.91M | 8.76M | 15.0M | 5.30M | 24.3M | 23.8M | 40.9M | 38.9M | 18.3M |
| Shareholders' Equity | -2.02M | 13.8M | 11.4M | 26.3M | 3.64M | -8.68M | -13.1M | -24.2M | -11.8M |
| Cash & Short-term Investments | 2.89M | 22.3M | 25.1M | 24.2M | 20.9M | 8.23M | 20.0M | 4.88M | 35.0K |
| Total Debt | - | - | - | - | - | 715K | 5.98M | 6.13M | 4.84M |
| Cash Flow | |||||||||
| Operating Cash Flow | -4.49M | -6.09M | -17.6M | -24.3M | -8.16M | -20.5M | -22.9M | -29.1M | -12.4M |
| Capital Expenditure | 1.00K | 15.0K | 698K | 677K | 174K | 367K | 530K | 82.0K | 65.3K |
| Free Cash Flow | - | -6.11M | -18.3M | -24.9M | -8.33M | -20.8M | -23.5M | -29.2M | -12.4M |
| Ratios | |||||||||
| ROE | - | -61.1% | -215.6% | -84.0% | -797.2% | - | - | - | - |
| ROA | -211.2% | -37.4% | -93.1% | -69.9% | -103.6% | -147.7% | -157.8% | -209.2% | 107.0% |
| Net Profit Margin | -286.6% | -371.2% | -2,867.0% | -801.8% | -2,836.2% | -2,233.3% | -2,754.5% | -159.7% | 26.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aridis Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2022 | - | - | - |
| 2021 | USD 4.13M | 0.34 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 1.36M | 0.43 | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
| 2015 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Aridis Pharmaceuticals Inc
- Insiders 0.00%
- Institutions 11.44%
- Public & others 88.56%
- Shares outstanding 44.6M
- Free float 40.3M
Top funds holding ARDS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Roumell Opportunistic Value Instl | 447K | 1.00% | 0.00% | Dec 2023 |
Top institutions holding ARDS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wealth Architects, LLC | 14.1K | 0.03% | 0.00% | Sep 2023 |
| State Street Corporation | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Cornerstone Wealth Management LLC | 0.00 | 0.00% | -100.00% | Sep 2023 |
| ICA Group Wealth Management, LLC | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Commonwealth Equity Services Inc | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Northern Trust Corp | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Roumell Asset Management, LLC | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Group One Trading, LP | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Vanguard Group Inc | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Vontobel Holding Ltd. | 0.00 | 0.00% | -100.00% | Sep 2023 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Sep 2023 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Sep 2023 |
| HRT FINANCIAL LLC | 0.00 | 0.00% | -100.00% | Sep 2023 |
Aridis Pharmaceuticals Inc company profile
- Company name
- Aridis Pharmaceuticals Inc
- Ticker
- ARDS.US
- Exchange
- USA Stocks
- Listed since
- Aug 10, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 37
- Fiscal year end
- December
- Address
- 983 University Avenue, Los Gatos, CA, United States, 95032
- Phone
- 408 385 1742
- Website
- aridispharma.com
About Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Aridis Pharmaceuticals Inc management
4- Dr. Eric J. Patzer Ph.D.Founder & Executive Chairman · born 1949
- Dr. Vu L. Truong Ph.D.Founder, CEO, Chief Scientific Officer & Director · born 1964
- Dr. Hasan Jafri M.D.Chief Medical Officer · born 1967
- Mr. Jeffrey J. Fessler Esq., J.D.Acting General Counsel · born 1963